Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| TROP2 expression as a prognostic predictor for osimertinib in patients with EGFR-mutant non-small cell lung cancer. | Transl Lung Cancer Res | 2026 | 42170286 | PubTator, text mining | PubMed |
| From biology to the clinic: research evidence and therapeutic advances of TROP2-targeted antibody-drug conjugates in small cell lung cancer. | Transl Lung Cancer Res | 2026 | 42170259 | PubTator, text mining | PubMed |
Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study. | Ann Oncol | 2026 | 42167437 | PubTator, text mining | PubMed |
| Reframing small cell lung cancer: therapeutic lessons from hematologic malignancies. | Front Oncol | 2026 | 42147254 | PubTator, text mining | PubMed |
| Small cell lung cancer: a therapeutic update in the era of immunotherapy and beyond-a narrative review. | Chin Clin Oncol | 2026 | 42145018 | PubTator, text mining | PubMed |
| Antibody-Mediated Delivery of BRM/BRG1 Protein Degraders Affords Strong Antitumor Efficacy in Multiple BRM-Dependent Non-Small Cell Lung Cancer Xenograft Models. | J Med Chem | 2026 | 42144767 | PubTator, text mining | PubMed |
| Cross-Platform Comparative Spatial Transcriptomics in High-Grade Serous Carcinoma. | Lab Invest | 2026 | 42142589 | PubTator, text mining | PubMed |
| Immuno-PET/CT Imaging of Trop2 Expression with [18F]AlF-RESCA-RT4 Enhances Diagnosis of Breast Cancers and the Metastases. | J Nucl Med | 2026 | 42134979 | PubTator, text mining | PubMed |
| A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer. | Clin Cancer Res | 2026 | 42132892 | PubTator, text mining | PubMed |
| A Phase II study of SHR-A1921, a TROP2-targeted antibody-drug conjugate, in patients with recurrent or metastatic salivary gland carcinoma. | NPJ Precis Oncol | 2026 | 42129335 | PubTator, text mining | PubMed |
| Research progress of antibody-drug conjugates in the treatment of endometrial cancer. | Front Oncol | 2026 | 42125712 | PubTator, text mining | PubMed |
| Bispecific Antibodies and Antibody-Drug Conjugates in Advanced Gastric Adenocarcinoma. | Cancers (Basel) | 2026 | 42122244 | PubTator, text mining | PubMed |
| Clinically relevant histopathological features and biomarkers in endometrial cancer. | Ceska Gynekol | 2026 | 42113616 | PubTator, text mining | PubMed |
| Expression of the antibody-drug conjugate targets TROP2, CLDN6, B7-H3, and DLL3 in mesonephric-like adenocarcinoma of the female genital tract. | Gynecol Oncol | 2026 | 42102523 | PubTator, text mining | PubMed |
| αTrop2/αCD3 bispecific protein engager-armed T cells (BATs) exhibit potent antitumor activity against nasopharyngeal carcinoma. | Cancer Immunol Immunother | 2026 | 42098361 | PubTator, text mining | PubMed |
| Promising New Platforms and Targets in the Management of Gastroesophageal Cancers. | Am Soc Clin Oncol Educ Book | 2026 | 42096664 | PubTator, text mining | PubMed |
| Targeting TROP2 and Exploiting AUNIP as a Determinant of ADC Cytotoxicity and Chemosensitivity in HNSCC and ESCA Cancers. | Mol Carcinog | 2026 | 42096614 | PubTator, text mining | PubMed |
| Dynamic modulation of intercellular adhesion mediated by matriptase-EPCAM/Trop-2 axes is critical for cell extrusion, division, and collective migration. | Cell Adh Migr | 2026 | 42087518 | PubTator, text mining | PubMed |
| Spatial Multiomics Reveal Insights Into ADC Efficacy. | Eur J Immunol | 2026 | 42083302 | PubTator, text mining | PubMed |
| Emerging therapies and translational advances in small cell lung cancer: Overcoming resistance. | Respir Investig | 2026 | 42054725 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=9